Aldeyra Therapeutics Inc

ALDX remains in an early/fragile Stage 1 consolidation base with accumulation signals from follow-through and exhaustion tags. Medium-term bias is bullish given the flattening 9/21 EMA regime and bottoming patterns, but price recently extended into resistance and is now pulling back. Short-term timing is neutral, so execution is deferred—stalking for pullbacks into the 9/21 EMA support zone.

• ↑Robust growth outlook supports market expansion in dry eye segment.
• ↑$100M+ cash as of Q1 2024 funds runway through 2027.
• ↓Net loss of $62M in FY22 heightens cash burn concerns.